Accordingly, low-risk patients elected to AS are more likely to be upgraded when presenting with small prostates, increased PSAD and BMI as well as with low ET levels, but high tumor load at prostate biopsy is the most important factor; however, these studies did not specifically investigate the low-risk cohort, but population sets including all risk classes having biopsy Gleason score 6 and PSA within 10 ng/mL; as result, these findings do not specifically apply for the low-risk category [20]. The gene discussed is KLK3; the disease is neoplasm.